Shire plc Shire Plc : Director/Pdmr Shareholding

TIDMSHP TIDMSHP 
 
 
 
   Director/PDMR Shareholding 
 
 
 
   August 23, 2017 
 
   - Shire plc (LSE: SHP, NASDAQ: SHPG) 
 
 
 
   Notification of transaction by person discharging managerial 
responsibilities 
 
 
 
 
 
     Details of the person discharging managerial responsibilities 
1.    ("PDMR") / person closely associated them ("PCA") 
a)   Name                      Sara Mathew 
2.   Reason for the notification 
a)   Position / status         Non-Executive Director (PDMR) 
     Initial notification / 
b)   amendment                 Initial notification 
     Details of the issuer, emission allowance participant, 
3.    auction platform, auctioneer or auction monitor 
a)   Name                      Shire plc 
b)   LEI                       54930005LQRLI2UXRQ59 
     Details of the transaction(s): section to be repeated 
      for (i) each type of instrument; (ii) each type of 
      transaction; (iii) each date; and (iv) each place 
4.    where transactions have been conducted 
     Description of the 
     financial instrument, 
a)   type of instrument        Shire plc American Depositary Shares ("ADSs") 
     Identification code       ISIN: US82481R1068 
     Nature of the 
b)   transaction               Acquisition of ADSs 
c)   Price(s) and volume(s)           Price(s)                Volume(s) 
                                              $143.23                    1,350 
d)   Aggregated information    N/A (single transaction) 
      - Aggregated volume 
      - Price 
e)   Date of the transaction   August 22, 2017 
f)   Place of the transaction  NASDAQ Global Select Market 
 
 
 
 
   Sarah Rixon 
 
   Company Secretarial Assistant 
 
   For further information please contact: 
 
 
 
 
 
 
Investor Relations 
Ian Karp             [e-mail]        [phone] 
Robert Coates        [e-mail]      [phone] 
Media 
Lisa Adler           [e-mail]   [phone] 
Debbi Ford           [e-mail]   [phone] 
 
 
 
 
   NOTES TO EDITORS 
 
 
 
   About Shire 
 
 
 
   Shire is the leading global biotechnology company focused on serving 
people with rare diseases. We strive to develop best-in-class products, 
many of which are available in more than 100 countries, across core 
therapeutic areas including Hematology, Immunology, Neuroscience, 
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal 
Medicine / Endocrine and Hereditary Angioedema; and a growing franchise 
in Oncology. 
 
 
 
   Our employees come to work every day with a shared mission: to develop 
and deliver breakthrough therapies for the hundreds of millions of 
people in the world affected by rare diseases and other high-need 
conditions, and who lack effective therapies to live their lives to the 
fullest. 
 
 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

August 23, 2017 07:15 ET (11:15 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.